These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32435496)

  • 1. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.
    Kang L; Zhang J; Li M; Xu N; Qi W; Tan J; Lou X; Yu Z; Sun J; Wang Z; Fu C; Tang X; Dai H; Chen J; Wu D; Yu L
    Biomark Res; 2020; 8():14. PubMed ID: 32435496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
    Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
    Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
    Stock S; Fertig L; Gottschlich A; Dörr J; Märkl F; Majed L; Menkhoff VD; Grünmeier R; Rejeski K; Cordas Dos Santos DM; Theurich S; von Bergwelt-Baildon M; Endres S; Subklewe M; Kobold S
    Cancer Immunol Immunother; 2024 Apr; 73(6):100. PubMed ID: 38630291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.
    Berahovich R; Zhou H; Xu S; Wei Y; Guan J; Guan J; Harto H; Fu S; Yang K; Zhu S; Li L; Wu L; Golubovskaya V
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30208593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
    Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
    Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
    Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
    Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
    Zanetti SR; Velasco-Hernandez T; Gutierrez-Agüera F; Díaz VM; Romecín PA; Roca-Ho H; Sánchez-Martínez D; Tirado N; Baroni ML; Petazzi P; Torres-Ruiz R; Molina O; Bataller A; Fuster JL; Ballerini P; Juan M; Jeremias I; Bueno C; Menéndez P
    Mol Ther; 2022 Feb; 30(2):550-563. PubMed ID: 34478871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
    Buonato JM; Edwards JP; Zaritskaya L; Witter AR; Gupta A; LaFleur DW; Tice DA; Richman LK; Hilbert DM
    Mol Cancer Ther; 2022 Jul; 21(7):1171-1183. PubMed ID: 35737298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.
    Wutti-In Y; Sujjitjoon J; Sawasdee N; Panya A; Kongkla K; Yuti P; Yongpitakwattana P; Thepmalee C; Junking M; Chieochansin T; Poungvarin N; Yamabhai M; Yenchitsomanus PT
    Front Oncol; 2021; 11():802876. PubMed ID: 35117999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
    Xu H; Guan C; Xu P; Zhou D; Xu Y; Chen B; Bai H
    Front Oncol; 2024; 14():1355643. PubMed ID: 38651157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
    Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
    J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
    Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
    Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.